GENinCode (LON:GENI) Trading 20% Higher – Time to Buy?

Shares of GENinCode Plc (LON:GENI) rose 20% during trading on Tuesday . The stock traded as high as GBX 1 and last traded at GBX 0.90. Approximately 6,863,559 shares were traded during mid-day trading, an increase of 22% from the average daily volume of 5,606,982 shares. The stock had previously closed at GBX 0.75.

GENinCode Trading Up 20.0%

The company has a market cap of £6.78 million, a price-to-earnings ratio of -0.43 and a beta of 0.59. The company’s 50 day moving average price is GBX 0.91 and its 200 day moving average price is GBX 1.09. The company has a debt-to-equity ratio of 117.74, a quick ratio of 15.88 and a current ratio of 0.93.

GENinCode (LON:GENI) last released its quarterly earnings data on Monday, June 8th. The company reported GBX (2.08) earnings per share (EPS) for the quarter. The business had revenue of GBX 308 million during the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. Research analysts anticipate that GENinCode Plc will post -7.1299999 EPS for the current year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.